Get started
Author

Francesca Primi

Observed names: F. Primi, FRANCESCA PRIMI, Primi Francesca, Primi, Francesca
ORCID: 0000-0001-6632-0486
Observed ORCID: 0000-0001-6632-0486
OpenAlex ID: A5045523492
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial
2026 · Serena Porcari, Chiara Ciccarese, et al. · Nature Medicine · 67
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?
2022 · CHIARA CICCARESE, ROBERTO IACOVELLI, et al. · Anticancer Research · 18
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study
2021 · F. Nelli, A. Fabbri, et al. · Annals of Oncology · 16
PDF
In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography
2003 · Silvia Mezi, Francesca Primi, et al. · International Journal of Oncology · 15
Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial).
2022 · Serena Porcari, Chiara Ciccarese, et al. · Journal of Clinical Oncology · 11
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study
2024 · Roberto Iacovelli, Chiara Ciccarese, et al. · European Urology · 10
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients
2022 · Enzo Maria Ruggeri, Fabrizio Nelli, et al. · Scientific Reports · 10
PDF
Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study
2021 · F. Nelli, A. Fabbri, et al. · Annals of Oncology · 9
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study
2021 · E.M. Ruggeri, F. Nelli, et al. · ESMO Open · 9
PDF
Solitary Fibrous Tumor/Hemangiopericytoma of the Penis: Report of the First Case
2014 · Daniele Castellani, Giancarlo Sebastiani, et al. · Urologia Journal · 9
Somatostatin receptor scintigraphy in metastatic breast cancer patients
2005 · Silvia Mezi, Francesca Primi, et al. · Oncology Reports · 9
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study
2022 · Fabrizio Nelli, Agnese Fabbri, et al. · International Immunopharmacology · 8
PDF
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study
2022 · F. Nelli, D. Giannarelli, et al. · Annals of Oncology · 8
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study
2023 · Fabrizio Nelli, Carlo Signorelli, et al. · Cancers · 7
PDF
Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival
2022 · MARIO GIOVANNI CHILELLI, CARLO SIGNORELLI, et al. · Cancer Diagnosis & Prognosis · 7
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors
2023 · Fabrizio Nelli, Diana Giannarelli, et al. · Cancer Immunology Immunotherapy · 6
PDF
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study
2023 · Fabrizio Nelli, Agnese Fabbri, et al. · Current Oncology · 5
PDF
Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study
2024 · Fabrizio Nelli, Agnese Fabbri, et al. · Clinical and Experimental Medicine · 4
PDF
Efficacy of perioperative pembrolizumab treatment in patients with resectable metastases from kidney cancer: The PE-PE study.
2024 · Roberto Iacovelli, Emanuela Fantinel, et al. · Journal of Clinical Oncology · 3
PDF
1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study
2023 · R. Iacovelli, C. Ciccarese, et al. · Annals of Oncology · 3
PDF
A phase II study of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma patients: NivoMet TWINS-GU002 Study
2025 · Chiara Ciccarese, Daniela Arduini, et al. · Tumori Journal · 2
Venous Thromboembolic Risk Does Not Increase After a Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine in Cancer Patients Receiving Active Systemic Therapies: Updated Results from the Vax-On-Third-Profile Study
2025 · Fabrizio Nelli, Enzo Maria Ruggeri, et al. · Vaccines · 1
PDF
Real-Life Experience of the Prognostic Significance of the Primary Tumor Location on the Timing of Colorectal Liver Metastases: A Retrospective Analysis
2022 · Carlo Signorelli, Pietro Maria Amodio, et al. · Cureus · 1
PDF
Impact of previous corticosteroid (CS) exposure on efficacy of programmed cell death-(Ligand) 1 blockade in patients with advanced non-small cell lung cancer (NSCLC): A single center retrospective analysis
2019 · F. Nelli, M.A. Fabbri, et al. · Annals of Oncology · 1
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy: A “real life” retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy.
2016 · Maria Agnese Fabbri, Paolo Marchetti, et al. · Journal of Clinical Oncology · 1
Works count: 37
Citation count: 236
H-index: 9
I10-index: 7
Year
Topic
Type